Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$23.73 -1.9%	$19.18	$16.10 ▼ $41.94	$3.06B	0.78	2.92 million shs	2.09 million shs
HCM HUTCHMED	$17.92 -0.4%	$16.33	$11.51 ▼ $21.50	$3.14B	0.55	40,915 shs	26,147 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
NUVB Nuvation Bio	$2.35 -1.0%	$2.20	$1.54 ▼ $3.45	$806.42M	1.35	4.80 million shs	4.64 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-1.94%	+24.89%	+36.22%	+32.70%	-32.41%
HCM HUTCHMED	-0.44%	-2.13%	+16.21%	+23.25%	-11.37%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
NUVB Nuvation Bio	-0.97%	-2.21%	+12.84%	+11.50%	-21.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.716 of 5 stars	4.3	3.0	0.0	4.4	3.8	2.5	0.6
HCM HUTCHMED	3.2473 of 5 stars	3.3	4.0	0.0	0.0	3.4	0.0	1.9
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	2.0099 of 5 stars	3.6	0.0	0.0	0.0	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.60	Moderate Buy	$36.83	55.22% Upside
HCM HUTCHMED	2.50	Moderate Buy	$28.00	56.25% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
NUVB Nuvation Bio	3.20	Buy	$7.17	205.35% Upside

Current Analyst Ratings Breakdown

Latest NUVB, HCM, APLS, and MOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$754.65M	3.97	N/A	N/A	$1.24 per share	19.14
HCM HUTCHMED	$630.20M	4.96	$0.29 per share	62.67	$4.43 per share	4.05
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
NUVB Nuvation Bio	$7.87M	101.47	N/A	N/A	$1.37 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	N/A
HCM HUTCHMED	$37.73M	N/A	0.00	12.27	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/7/2025 (Estimated)

Latest NUVB, HCM, APLS, and MOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
HCM HUTCHMED	0.08	2.83	2.70
MOR MorphoSys	4.98	1.38	1.38
NUVB Nuvation Bio	N/A	9.01	9.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
HCM HUTCHMED	8.82%
MOR MorphoSys	18.38%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
HCM HUTCHMED	3.60%
MOR MorphoSys	0.05%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable

NUVB, HCM, APLS, and MOR Headlines

Recent News About These Companies

Nuvation Bio (NUVB) to Release Quarterly Earnings on Thursday

August 5 at 2:52 AM | americanbankingnews.com

Brokerages Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $7.17

August 4 at 2:09 AM | americanbankingnews.com

Nuvation Bio Inc. (NYSE:NUVB) Given Average Rating of "Buy" by Brokerages

August 2, 2025 | marketbeat.com

Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment

August 1, 2025 | finance.yahoo.com

GSA Capital Partners LLP Has $1.16 Million Stock Position in Nuvation Bio Inc. (NYSE:NUVB)

August 1, 2025 | marketbeat.com

RBC Capital Maintains a Buy on Nuvation Bio (NUVB) With a $6 PT

August 1, 2025 | msn.com

Institutional investors may adopt severe steps after Nuvation Bio Inc.'s (NYSE:NUVB) latest 5.9% drop adds to a year losses

July 31, 2025 | finance.yahoo.com

Nuvation Bio (NUVB) Expected to Announce Earnings on Thursday

July 31, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Trading 8.6% Higher - Should You Buy?

July 29, 2025 | marketbeat.com

Wall Street Zen Upgrades Nuvation Bio (NYSE:NUVB) to Hold

July 28, 2025 | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Upgraded at Wall Street Zen

July 26, 2025 | marketbeat.com

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

July 24, 2025 | businesswire.com

Nuvation Bio (NYSE:NUVB) Trading Up 5.4% - What's Next?

July 16, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Stock Price Down 5.2% - Should You Sell?

July 14, 2025 | marketbeat.com

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade ... - Nasdaq

July 11, 2025 | nasdaq.com

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy

July 9, 2025 | zacks.com

Nuvation Bio (NYSE:NUVB) Shares Gap Up - What's Next?

July 9, 2025 | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from Brokerages

July 7, 2025 | marketbeat.com

Nuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo Finance

July 2, 2025 | uk.finance.yahoo.com

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

June 29, 2025 | msn.com

RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating

June 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB, HCM, APLS, and MOR Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$23.73 -0.47 (-1.94%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$21.00 -2.73 (-11.50%)

As of 04:00 AM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

HUTCHMED NASDAQ:HCM

$17.92 -0.08 (-0.44%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$26.00 +8.08 (+45.09%)

As of 04:00 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/5/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Nuvation Bio NYSE:NUVB

$2.35 -0.02 (-0.97%)

Closing price 08/6/2025 03:59 PM Eastern

Extended Trading

$2.36 +0.01 (+0.34%)

As of 06:09 AM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time